Major Finding: Healthy adults had immunogenic responses of 84% to influenza A(H1N1), 71% to influenza A(H3N2), and 61% to influenza B when the pneumococcal vaccine and the trivalent influenza vaccine were given together.
Data Source: Randomized, double blind, phase III clinical trials in over 1,000 healthy adults.
Disclosures: The study was funded by Pfizer Inc. Dr. Frenck said he had no other conflict to declare. Several of the coauthors are Pfizer employees.
ATLANTA — In healthy adults, the 13-valent pneumococcal conjugate vaccine can be safely administered at the same time as trivalent inactivated influenza vaccine without compromising immunogenicity, reported Dr. Robert W. Frenck Jr. of Cincinnati Children's Hospital Medical Center and colleagues.
PCV13 is not approved for use in adults, but “likely will be in the not-too-distant future, and this study will help clinicians decide how to administer the vaccine,” Dr. Frenck said.
The findings from randomized, double blind, phase III clinical trials were presented in a poster at the conference, sponsored by the Centers for Disease Control and Prevention.
For the study, 1,116 healthy adults aged 50–59 years were randomized to receive either PCV13 and TIV (PCV13+TIV) followed by placebo 1 month later, or TIV and placebo (TIV+placebo) followed by PCV13 1 month later.
“Noninferiority of PCV13+TIV to TIV+placebo was demonstrated for all virus subtypes,” investigators reported. The PCV13+TIV and TIV+placebo groups each had similar proportions of responders with a fourfold increase in TIV antibody titer (see chart).
Similarly, for the PCV13, investigators reported that the noninferiority criterion was met for all serotypes.
Most adverse events were mild; none was serious. Local reactions occurred in 89% of PCV13+TIV recipients vs. 39% in recipients of TIV+placebo and 85% of those receiving PCV13 alone. Systemic events occurred in 86% of PCV13+TIV recipients, 76% of recipients of TIV+placebo, and 77% of those receiving PCV13 alone.
Vitals
Source Elsevier Global Medical News